염증성 장질환에서의 종양 괴사 인자 억제제와 결핵 = Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease

참고문헌 (Reference)

1 Gottlieb AB, "Tumor necrosis factor blockade : mechanism of action" 12 : 1-4, 2007

2 Sichletidis L, "Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis" 10 : 1127-1132, 2006

3 Carpio D, "Tuberculosis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures : compliance with recommendations and safety of retreatment" 10 : 1186-1193, 2016

4 Keane J, "Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent" 345 : 1098-1104, 2001

5 van Dullemen HM, "Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody(cA2)" 109 : 129-135, 1995

6 Ai JW, "The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-αantagonist : a metaanalysis of both randomized controlled trials and registry/cohort studies" 42 : 2229-2237, 2015

7 Roach DR, "TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection" 168 : 4620-4627, 2002

8 Byun JM, "Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor" 50 : 312-320, 2015

9 Navarra SV, "Risk of tuberculosis with anti-tumor necrosis factor-α therapy : substantially higher number of patients at risk in Asia" 17 : 291-298, 2014

10 Jung SM, "Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy : a nationwide study in South Korea, a country with an intermediate tuberculosis burden" 18 : 323-330, 2015

11 Minozzi S, "Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis : a systematic review and meta-analysis" 15 (15): 11-34, 2016

12 송혜경, "Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn’s and Colitis (AOCC) meeting in Seoul" 대한장연구학회 14 (14): 240-247, 2016

13 "Programmatic management of latent tuberculosis infection in the European Union" European Centre for Disease Prevention and Control

14 Getahun H, "Latent Mycobacterium tuberculosis infection" 373 : 1179-1180, 2015

15 Mack U, "LTBI : latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement" 33 : 956-973, 2009

16 Deepak P, "Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease : analysis of the Food and Drug Administration Adverse Event Reporting System" 22 : 269-276, 2013

17 Flynn JL, "Immunology of tuberculosis" 19 : 93-129, 2001

18 Kwak MS, "Emerging trends of inflammatory bowel disease in South Korea : a nationwide population-based study" 34 : 1018-1026, 2019

19 Dixon WG, "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy : results from the British Society for Rheumatology Biologics Register(BSRBR)" 69 : 522-528, 2010

20 Dong Il Park, "Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management" 대한장연구학회 16 (16): 17-25, 2018

21 Feldmann M, "Anti-TNF alpha therapy of rheumatoid arthritis : what have we learned" 19 : 163-196, 2001

22 Caporali R, "20 years of experience with tumour necrosis factor inhibitors: what have we learned?" 57 (57): vii5-vii10, 2018